Answers are grounded in this paper and cite their sources.
Exenatide was the first marketed GLP-1 receptor agonist for the treatment of type 2 diabetes. Modification to the chemical structure or the formulation has the potential to increase the stability of exenatide. We introduced human complex-type sialyloligosaccharide to exenatide at the native Asn28 position. The synthesis was achieved using both solid phase peptide synthesis (SPPS) and Omniligase-1-mediated chemoenzymatic ligation. The results demonstrate that glycosylation increases the proteolytic stability of exenatide while retaining its full biological activity.
No takes yet. Share an insight, caveat, or question.
Chandrashekar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: